On this page
Inside the research
Follow the signal through the study
MOTS-c was lower in the sampled muscle and serum; humanin showed a different circulating pattern. A tissue association does not establish that replacing a peptide improves kidney disease or muscle function.
Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease.
- Biological setting
- People with stage-5 chronic kidney disease and age-matched controls.
- What was measured
- Muscle peptide expression, circulating levels and mitochondrial/oxidative features.
- Observed signal
- MOTS-c was lower in the sampled muscle and serum; humanin showed a different circulating pattern.
- Remaining gap
- A tissue association does not establish that replacing a peptide improves kidney disease or muscle function.
- How it was tested
- Human tissue and serum comparison.
Where this story begins
The starting point is people with stage-5 chronic kidney disease and age-matched controls. The investigators used human tissue and serum comparison, looking at muscle peptide expression, circulating levels and mitochondrial/oxidative features. The central evidence guide explains the broader distinction before any product decision is considered.
What the paper found
MOTS-c was lower in the sampled muscle and serum; humanin showed a different circulating pattern. A tissue association does not establish that replacing a peptide improves kidney disease or muscle function.
The detail worth keeping
Measuring more than one compartment helps reveal why a single blood number may not describe local biology. The contrasting humanin result also cautions against treating mitochondrial-derived peptides as a uniform class. Severe kidney disease changes metabolism and clearance in ways that can affect interpretation. Any proposed intervention would require direct safety and outcome evidence in that population.
A neighboring piece of evidence
The next evidence note stays with muscle, fatigue and tissue measurement. It examines small matched groups with Q-fever fatigue, chronic fatigue and control states and follows mitochondrial peptide-coding transcripts and related measurements. Transcript levels are not a prescription target, and no MOTS-c therapy was tested. Read the two sources as different tests within that subject, keeping their intervention and measurement boundaries visible rather than combining them into a single benefit claim.
Bring a specific question
The consultation question list can distinguish evidence about a biomarker from evidence about treatment. In severe kidney disease, exposure and safety need direct evaluation in the relevant population. This study does not establish that a marketed peptide restores muscle function or that a blood test identifies a deficit to replace.
Read the source
Research findings and provider statements are different evidence.